Diabetes: Anti-PCSK9 antibodies - beneficial or inducers of diabetes?
- PMID: 29118349
- DOI: 10.1038/nrendo.2017.145
Diabetes: Anti-PCSK9 antibodies - beneficial or inducers of diabetes?
Comment on
-
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.Lancet Diabetes Endocrinol. 2017 Dec;5(12):941-950. doi: 10.1016/S2213-8587(17)30313-3. Epub 2017 Sep 15. Lancet Diabetes Endocrinol. 2017. PMID: 28927706 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
